Walleye Capital
NVAX icon

Walleye Capital’s Novavax NVAX Stock Holding History

Walleye Capital’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$352K Sell
43,200
-56,700
-57% -$514K ﹤0.01% 2940
2025
Q4 		$671K Sell
99,900
-52,600
-34% -$397K ﹤0.01% 2745
2025
Q3 		$1.32M Buy
152,500
+32,200
+27% +$251K 0.01% 1877
2025
Q2 		$758K Buy
120,300
+101,400
+537% +$671K ﹤0.01% 2279
2025
Q1 		$121K Sell
18,900
-20,600
-52% -$170K ﹤0.01% 3539
2024
Q4 		$318K Sell
39,500
-6,400
-14% -$61.7K ﹤0.01% 3373
2024
Q3 		$580K Sell
45,900
-67,300
-59% -$869K ﹤0.01% 3159
2024
Q2 		$1.43M Buy
113,200
+100,800
+813% +$1.01M ﹤0.01% 2451
2024
Q1 		$59.3K Buy
+12,400
New +$57.5K ﹤0.01% 4624
2023
Q3 		– Sell
-12,100
Closed -$89.9K – 5186
2023
Q2 		$89.9K Sell
12,100
-2,700
-18% -$21.2K ﹤0.01% 3467
2023
Q1 		$103K Sell
14,800
-6,100
-29% -$56.1K ﹤0.01% 2918
2022
Q4 		$215K Sell
20,900
-17,600
-46% -$311K ﹤0.01% 1993
2022
Q3 		$701K Buy
+38,500
New +$1.67M 0.01% 1208

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's NVAX Position: Q1 2026 in Review

Walleye Capital reduced its Novavax (NVAX) stake by 58% in Q1 2026, selling an estimated $468K and leaving 37,920 shares worth $309K. The position accounts for ﹤0.01% of the portfolio, ranked #3045.

Walleye Capital first reported a position in NVAX in Q1 2022 and has held it in 13 quarters since. The position peaked at $4.99M in Q2 2024. 257 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • Walleye Capital held 37,920 shares of Novavax worth $309K as of Q1 2026.
  • Walleye Capital sold 51,639 Novavax shares in Q1 2026, an estimated $468K.
  • Novavax made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3045 holding.
  • Walleye Capital first reported a position in Novavax in Q1 2022 and has held it in 13 quarters since.
  • Walleye Capital's Novavax position peaked at $4.99M in Q2 2024.
  • 257 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.